Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Judy Hopking

Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Antiviral Therapy

Infectious Diseases

Pharmacology

2017

English

Related publications

Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project

Infection and Drug Resistance

Infectious Diseases

Pharmacology

2019

English

Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir

AIDS Research and Human Retroviruses

English

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

Alimentary Pharmacology and Therapeutics

English

A Multi-National, Randomised, Open-Label, Parallel, Phase III Non-Inferiority Study Comparing NK105 and Paclitaxel in Metastatic or Recurrent Breast Cancer Patients

British Journal of Cancer

Cancer Research

Oncology

2019

English

Efficacy of Bimin Decoction for Patients With Perennial Allergic Rhinitis: An Open-Label Non-Inferiority Randomized Controlled Trial

English

Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology

Allergy

Immunology

2019

English

96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study

English

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Clinical Therapeutics

Pharmacology

2016

English

Dihydroartemisinin-Piperaquine Versus Chloroquine to Treat Vivax Malaria in Afghanistan: An Open Randomized, Non-Inferiority, Trial

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Judy Hopking

Dolutegravir/Abacavir/Lamivudine Versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study

Related publications

Lipid Profile Improvement in Virologically Suppressed HIV-1-infected Patients Switched to Dolutegravir/Abacavir/Lamivudine: Data From the SCOLTA Project

Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching From Ritonavir-Boosted Protease Inhibitors to Raltegravir

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

A Multi-National, Randomised, Open-Label, Parallel, Phase III Non-Inferiority Study Comparing NK105 and Paclitaxel in Metastatic or Recurrent Breast Cancer Patients

Efficacy of Bimin Decoction for Patients With Perennial Allergic Rhinitis: An Open-Label Non-Inferiority Randomized Controlled Trial

Prospective Open-Label Study of 48-Week Subcutaneous Administration of Mepolizumab in Japanese Patients With Severe Eosinophilic Asthma

96-Week Results of Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Plus Efavirenz, in Antiretroviral-Naive, HIV-1-infected Adults: ASSERT Study

Long-Term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-Center, Open-Label, Phase IIIb Study

Dihydroartemisinin-Piperaquine Versus Chloroquine to Treat Vivax Malaria in Afghanistan: An Open Randomized, Non-Inferiority, Trial